ST
RPRX icon

Smithfield Trust’s Royalty Pharma RPRX Stock Holding History

Smithfield Trust’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$28K Hold
603
– – ﹤0.01% 701
2025
Q4 		$23K Sell
603
-7
-1% -$267 ﹤0.01% 733
2025
Q3 		$21K Buy
+610
New +$22.1K ﹤0.01% 735

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Smithfield Trust's RPRX Position: Q1 2026 in Review

Smithfield Trust held its Royalty Pharma (RPRX) position steady in Q1 2026 at 603 shares worth $28K. The position accounts for ﹤0.01% of the portfolio, ranked #701.

Smithfield Trust first reported a position in RPRX in Q3 2025 and has held it in 3 quarters since. 587 funds tracked by Wall St. Rank hold RPRX as of Q1 2026.

  • Smithfield Trust held 603 shares of Royalty Pharma worth $28K as of Q1 2026.
  • Smithfield Trust left its Royalty Pharma share count unchanged in Q1 2026.
  • Royalty Pharma made up ﹤0.01% of Smithfield Trust's portfolio in Q1 2026, its #701 holding.
  • Smithfield Trust first reported a position in Royalty Pharma in Q3 2025 and has held it in 3 quarters since.
  • 587 funds tracked by Wall St. Rank held Royalty Pharma as of Q1 2026.

Based on Smithfield Trust's 13F filing for Q1 2026, filed 8 May 2026.